AbCellera Biologics (ABCL) Earnings Analysis
AbCellera Biologics (ABCL) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it beat with EPS -0.14 USD vs -0.22 USD est (+36.4%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -11.94.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ABCL next report earnings?
No confirmed upcoming earnings date is currently scheduled for ABCL. This page updates as the calendar is published.
ABCL earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.14 USD | -0.22 USD | +36.4% | Beat |
| 2025-11-06 | -0.19 USD | -0.17 USD | -11.8% | Miss |
| 2025-02-27 | -0.11 USD | -0.15 USD | +26.7% | Beat |
| 2024-11-04 | -0.17 USD | -0.14 USD | -21.4% | Miss |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
ABCL valuation and analyst view
| Trailing P/E | -11.94 |
|---|---|
| Trailing EPS | -0.47499 USD |
| Price / book | 1.85 |
| Dividend yield | 0.00% |
| Market cap | 1.79B |
| Analyst consensus | Buy (10 buy / 1 hold / 0 sell) |
| Avg price target | 7.5 USD |
Related research pages
Frequently asked questions
When is AbCellera Biologics (ABCL)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ABCL. This page updates as the calendar is published.
Did ABCL beat earnings last quarter?
In its 2026-05-11 report, ABCL posted EPS of -0.14 USD versus a -0.22 USD estimate — a beat of 36.4%.
What is ABCL's earnings track record?
Over the last 4 reported quarters with consensus data, ABCL beat estimates 2 times (50%).
What is ABCL's current P/E ratio and EPS?
ABCL trades at a trailing P/E of -11.94 on trailing EPS of -0.47498535880299175 USD.
What do analysts rate ABCL?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 7.5 USD.